(Q46043763)

19 December 2017

title

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer (English)

1 reference

19 December 2017

1 reference

6

James P Allison

0 references

author name string

Eric J Small

1

1 reference

19 December 2017

N Simon Tchekmedyian

2

1 reference

19 December 2017

Brian I Rini

3

1 reference

19 December 2017

Lawrence Fong

4

1 reference

19 December 2017

Israel Lowy

5

1 reference

19 December 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

19 December 2017

published in

Clinical Cancer Research

1 reference

19 December 2017

volume

13

1 reference

19 December 2017

page(s)

1810-1815

1 reference

19 December 2017

issue

6

1 reference

19 December 2017

Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer

cites work

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2318

CD28-B7 interactions in T-cell activation.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2318

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2318

Enhancement of antitumor immunity by CTLA-4 blockade

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2318

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2318

CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2318

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2318

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2318

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2318

Cancer statistics, 2006

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2318

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2318

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2318

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2318

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1078-0432.CCR-06-2318

Identifiers

DOI

10.1158/1078-0432.CCR-06-2318

1 reference

19 December 2017

PubMed ID

17363537

1 reference

19 December 2017